Jun 22, 2020 / 04:30PM GMT
Operator
Good afternoon. My name is Shannon, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics DLBCL approval conference call.
(Operator Instructions)
Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Mr. Ian Karp, Karyopharm's Vice President, Investor and Public Relations.
Ian Karp - Karyopharm Therapeutics Inc. - VP of Investor & Public Relations
Thanks so much, Shannon, and thank you all for joining us on today's conference call to discuss the accelerated FDA approval of XPOVIO for the treatment of patients with relapsed or refractory DLBCL. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, Chief Executive Officer; Mr. John Demaree, Chief Commercial Officer; Dr. Jatin Shah, Chief Medical Officer; Mr. Chris Primiano, Chief Business Officer and General Counsel; and Mr. Mike Mason, Chief Financial Officer. On the call today, Dr. Kauffman will review the details regarding the accelerated
Karyopharm Therapeutics Inc to Discuss The FDA's Approval Of XPOVIO Transcript
Jun 22, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers